Few medications are as infamous as thalidomide: in the late 1950's the drug, prescribed to pregnant women as a mild sedative and morning sickness remedy, caused severe congenital malformations in tens of thousands of newborns. The case had significant ramifications for the drug industry, with agencies around the world, including the U.S. Food and Drug Administration, restructuring their rules for drug use and approval. In the ensuing years, the name thalidomide became synonymous with medical disaster and the need for safeguards in drug development. Yet, unexpectedly and without much fanfare, thalidomide is getting a second chance, proving its usefulness in treating diseases as disparate as cancer and leprosy. Indeed, due to its immunomodulatory and antiproliferative properties, thalidomide has quietly become an important treatment option for multiple myeloma.
As thalidomide and its derivatives make their way back into hospitals, research follows, seeking to uncover the mechanisms of its seemingly incongruent physiological effects. Two new studies from the laboratories of Nicolas Thomä and Philip Chamberlain (Chamberlain et al., 2014; Fischer et al., 2014) describe the structure of thalidomide and its derivatives bound to a previously identified target, the ubiquitously expressed protein cereblon that is part of the cullin-4-containing E3 ubiquitin ligase complex CUL4-RBX1-DDB1. These papers follow on the heels of three studies published earlier this year by Benjamin Ebert, William Kaelin, and Rajesh Chopra (Krö nke et al., 2014; Lu et al., 2014 , Gandhi et al., 2014 , showing that the antiproliferative effect of thalidomide on multiple myeloma arises from its ability to activate cereblon's E3-ligase activity, resulting in the ubiquitination and degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This selective targeting results in the dysregulation of B and T cell development, underlying thalidomide's ability to affect the immune system.
Using structural approaches, Thomä and Chamberlain provide further molecular insights into this interaction. In their study, Chamberlain and colleagues describe how thalidomide derivatives bind to cereblon and the CUL4-RBX1-DDB1 complex, identifying key features of the structure and the residues critical for the antiproliferative action of the drugs. The Thomä lab analyzed the structure of the complex aiming to dissect the effects of thalidomide on cereblon's E3 ligase activity. They find that thalidomide binding to cereblon and the subsequent degradation of Ikaros interferes with the recruitment and regulation of a previously unknown endogenous substrate, the transcription factor MEIS2, which then becomes upregulated. Thus, thalidomide influences two distinct cellular pathways, inducing both loss-and gain-of-function changes that may account for its pleiotropic effects.
These and other advances have brought renewed interest in this controversial drug, which, if not fully rehabilitated, provides clear benefits to targeted patient populations. The insights into its mode of action lift a curtain on a previously inscrutable compound and provide much needed understanding of it effects, supporting the development of new and safer derivatives. Indeed, the example of thalidomide shows that examining the biology of drugs that were disfavored for various reasons is valuable for both fundamental and clinical advances.
